Sign In
Buy PFE
$27.05
+0.290 (+1.08%)
At Close: Aug 10, 2026
Nike Names Pfizer's Denton as Next CFO
04:24pm, Tuesday, 23'rd Jun 2026
David Denton's appointment, effective Aug. 17, comes as the company struggles to execute its turnaround.
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
01:55pm, Tuesday, 23'rd Jun 2026
Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose
Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform
01:49pm, Tuesday, 23'rd Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems and PBPK modeling for predicting human pha
Major Indexes Continue Lower as Chip Selloff Drags Nasdaq
12:18pm, Tuesday, 23'rd Jun 2026
Stocks are continuing lower amid the global tech selloff, with the Nasdaq Composite (IXIC) off nearly 500 points
China outpacing Europe in drug innovation and development, Pfizer executive says
12:10pm, Tuesday, 23'rd Jun 2026
China has pulled ahead of Europe in pharmaceutical innovation and drug development, a senior Pfizer executive said on Tuesday.
Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
10:30am, Tuesday, 23'rd Jun 2026
PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.
Pfizer's experimental drug misses main goal of lung cancer trial
04:43pm, Monday, 22'nd Jun 2026
Pfizer said on Monday its drug for a type of lung cancer missed the main goal of a late-stage trial.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigationa
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow
04:02pm, Monday, 22'nd Jun 2026
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry.
Pfizer Stock Edges Lower Monday: What's Going On?
10:35am, Monday, 22'nd Jun 2026
Pfizer Inc. (NYSE:PFE) shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat. Here's what investors need to know.
Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead
07:58am, Monday, 22'nd Jun 2026
Pfizer has leaned on acquisitions in recent years to strengthen its growth prospects. Acquisitions, however, can add costs and lead to inefficiency.
Could Pfizer Stock Be Your Ticket to Generational Wealth?
09:15pm, Sunday, 21'st Jun 2026
Pfizer is one of the world's most respected pharmaceutical companies. Pfizer is working through a normal product cycle in the drug sector.
Own 500 Shares of Pfizer and JNJ and Here's Your Annual Dividend Income
11:30am, Sunday, 21'st Jun 2026
Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
05:15pm, Saturday, 20'th Jun 2026
Eli Lilly is a market darling because it is a leader in the GLP-1 weight-loss market. Pfizer hasn't even entered the GLP-1 race yet, which is one reason why its shares are comparatively unloved.
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
11:25am, Friday, 19'th Jun 2026
Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.
